一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Clinical Pharmacokinetics >>article
Clinical Pharmacokinetics

Clinical Pharmacokinetics

IF: 4.59
Download PDF

Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review.

Published:1 April 2023 DOI: 10.1007/s40262-023-01225-7 PMID: 37000342
T Y J Appeldoorn, T H Oude Munnink, L M Morsink, M N Lub-de Hooge, D J Touw

Abstract

Background and objective: Ruxolitinib is a tyrosine kinase inhibitor targeting the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways. Ruxolitinib is used to treat myelofibrosis, polycythemia vera and steroid-refractory graft-versus-host disease in the setting of allogeneic stem-cell transplantation. This review describes the pharmacokinetics and pharmacodynamics of ruxolitinib.

Methods: Pubmed, EMBASE, Cochrane Library and web of Science were searched from the time of database inception to march 15, 2021 and was repeated on November 16, 2021. Articles not written in English, animal or in vitro studies, letters to the editor, case reports, where ruxolitinib was not used for hematological diseases or not available as full text were excluded.

Results: Ruxolitinib is well absorbed, has 95% bio-availability, and is bound to albumin for 97%. Ruxolitinib pharmacokinetics can be described with a two-compartment model and linear elimination. Volume of distribution differs between men and women, likely related to bodyweight differences. Metabolism is mainly hepatic via CYP3A4 and can be altered by CYP3A4 inducers and inhibitors. The major metabolites of ruxolitinib are pharmacologically active. The main route of elimination of ruxolitinib metabolites is renal. Liver and renal dysfunction affect some of the pharmacokinetic variables and require dose reductions. Model-informed precision dosing might be a way to further optimize and individualize ruxolitinib treatment, but is not yet advised for routine care due to lack of information on target concentrations.

Conclusion: Further research is needed to explain the interindividual variability of the ruxolitinib?pharmacokinetic variables and to optimize individual treatment.

Substances (2)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Ruxolitinib 941678-49-5 C17H18N6 460 suppliers $10.00-$2757.40
P450 3A4 40 suppliers Inquiry

Similar articles

IF:1.9

A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.

European Journal of Drug Metabolism and Pharmacokinetics Kyle John Wilby,etc Published: 1 June 2018
IF:4.6

Clinical pharmacokinetics and pharmacodynamics of linagliptin.

Clinical Pharmacokinetics Ulrike Graefe-Mody, Silke Retlich,etc Published: 1 July 2012
民县| 高平市| 疏勒县| 法库县| 中宁县| 阳高县| 安丘市| 普定县| 云安县| 庆安县| 文成县| 涿州市| 札达县| 合江县| 长顺县| 余庆县| 阳新县| 宜都市| 平陆县| 东阳市| 高安市| 西乌珠穆沁旗| 阿鲁科尔沁旗| 泸州市| 天气| 渑池县| 黔西| 镇巴县| 抚远县| 衡山县| 泰兴市| 新津县| 靖边县| 昌江| 黔西县| 乌兰察布市| 清涧县| 卢龙县| 饶河县| 惠安县| 平阴县|